Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Assets (2019 - 2025)

Allogene Therapeutics' Current Assets history spans 7 years, with the latest figure at $260.7 million for Q3 2025.

  • For Q3 2025, Current Assets fell 14.35% year-over-year to $260.7 million; the TTM value through Sep 2025 reached $260.7 million, down 14.35%, while the annual FY2024 figure was $303.4 million, 33.92% down from the prior year.
  • Current Assets for Q3 2025 was $260.7 million at Allogene Therapeutics, down from $282.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $716.1 million in Q1 2021 and bottomed at $260.7 million in Q3 2025.
  • The 5-year median for Current Assets is $471.3 million (2021), against an average of $451.8 million.
  • The largest YoY upside for Current Assets was 41.96% in 2021 against a maximum downside of 44.23% in 2021.
  • A 5-year view of Current Assets shows it stood at $471.3 million in 2021, then increased by 12.2% to $528.8 million in 2022, then fell by 13.18% to $459.1 million in 2023, then crashed by 33.92% to $303.4 million in 2024, then fell by 14.06% to $260.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Current Assets are $260.7 million (Q3 2025), $282.7 million (Q2 2025), and $291.6 million (Q1 2025).